Video

Revolutionizing Targeted Therapy With EGFR Exon 20 and the Early-Stage NSCLC Setting

Author(s):

Joshua Sabari, MD,Balazs Halmos, MD

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, discuss the updates with targeted therapy as it relates to the early-stage setting of non–small cell lung cancer as well as those who harbor EGFR exon 20 insertion mutations.

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, discuss the updates with targeted therapy as it relates to the early-stage setting of non–small cell lung cancer as well as those who harbor EGFR exon 20 insertion mutations.

Funding from Daiichi Sankyo/Content Independently Developed by OncLive

Related Videos
Josh Sabari, MD
Balazs Halmos, MD; Nicholas C. Rohs, MD; Josh Sabari, MD
Josh Sabari, MD, of NYU Grossman School of Medicine
Reviewing the Year 2021 in Lung Cancer Treatment
Isabel Preeshagul, DO, MBS
Ashish Saxena, MD, PhD, and Catherine Ann Shu, MD
Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD
Jamie Chaft, MD, and Vamsidhar Velcheti, MD
Joshua K. Sabari, MD
Related Content